Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 227

1.

Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.

Stathopoulos GP, Rigatos SK, Dimopoulos MA, Giannakakis T, Foutzilas G, Kouroussis C, Janninis D, Aravantinos G, Androulakis N, Agelaki S, Stathopoulos JG, Georgoulias V; Greek Cooperative Group for Pancreatic Cancer.

Ann Oncol. 2003 Mar;14(3):388-94.

PMID:
12598343
[PubMed - indexed for MEDLINE]
Free Article
2.

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.

Stathopoulos GP, Syrigos K, Polyzos A, Fountzilas G, Rigatos SK, Ziras N, Potamiannou A, Tsiakopoulos I, Androulakis N, Aravantinos G, Athanasiadis A, Papakotoulas P, Georgoulias V.

Ann Oncol. 2004 Feb;15(2):224-9.

PMID:
14760113
[PubMed - indexed for MEDLINE]
Free Article
3.

Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.

Kakolyris S, Papadakis E, Tsiafaki X, Kalofonos C, Rapti A, Toubis M, Bania E, Kouroussis C, Chainis K, Androulakis N, Agelaki S, Sarra E, Vardakis N, Georgoulias V; Greek Cooperative Group for Lung Cancer.

Lung Cancer. 2001 May;32(2):179-87.

PMID:
11325489
[PubMed - indexed for MEDLINE]
4.

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW.

Oncologist. 2001;6(6):488-95.

PMID:
11743211
[PubMed - indexed for MEDLINE]
Free Article
5.

Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.

Stathopoulos GP, Mavroudis D, Tsavaris N, Kouroussis C, Aravantinos G, Agelaki S, Kakolyris S, Rigatos SK, Karabekios S, Georgoulias V.

Ann Oncol. 2001 Jan;12(1):101-3.

PMID:
11249034
[PubMed - indexed for MEDLINE]
Free Article
6.

Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.

Pectasides D, Aravantinos G, Kalofonos H, Kiamouris C, Bafaloukos D, Xiros N, Nicolaides C, Visvikis A, Dimopoulos MA.

Ann Oncol. 2001 Oct;12(10):1417-22.

PMID:
11762814
[PubMed - indexed for MEDLINE]
Free Article
7.

Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.

Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, Kozuch P.

Anticancer Drugs. 2007 Mar;18(3):263-71.

PMID:
17264757
[PubMed - indexed for MEDLINE]
8.

Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.

Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P.

Cancer Invest. 2003;21(4):489-96.

PMID:
14533437
[PubMed - indexed for MEDLINE]
9.

Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study.

Pectasides D, Mylonakis N, Farmakis D, Nikolaou M, Koumpou M, Katselis I, Gaglia A, Kostopoulou V, Karabelis A, Kosmas C.

Anticancer Res. 2003 Sep-Oct;23(5b):4205-11.

PMID:
14666626
[PubMed - indexed for MEDLINE]
10.

Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.

Xiros N, Papacostas P, Economopoulos T, Samelis G, Efstathiou E, Kastritis E, Kalofonos H, Onyenadum A, Skarlos D, Bamias A, Gogas H, Bafaloukos D, Samantas E, Kosmidis P.

Ann Oncol. 2005 May;16(5):773-9. Epub 2005 Mar 31.

PMID:
15802284
[PubMed - indexed for MEDLINE]
Free Article
11.

Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.

Neri B, Cipriani G, Grifoni R, Molinara E, Pantaleo P, Rangan S, Vannini A, Tonelli P, Valeri A, Pantalone D, Taddei A, Bechi P.

Oncol Res. 2009;17(11-12):559-64.

PMID:
19806786
[PubMed - indexed for MEDLINE]
12.

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL.

J Clin Oncol. 2004 Sep 15;22(18):3776-83.

PMID:
15365074
[PubMed - indexed for MEDLINE]
13.

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.

Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S, Cortes-Funes H.

J Clin Oncol. 1999 Feb;17(2):585-92.

PMID:
10080603
[PubMed - indexed for MEDLINE]
14.

A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.

Kakolyris SS, Kouroussis C, Koukourakis M, Kalbakis K, Mavroudis D, Vardakis N, Georgoulias V.

Anticancer Res. 2002 May-Jun;22(3):1891-6.

PMID:
12168889
[PubMed - indexed for MEDLINE]
15.

Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.

Endlicher E, Troppmann M, Kullmann A, Golder S, Herold T, Herfarth H, Grossmann J, Schlottmann K, Kullmann F.

Oncology. 2007;72(5-6):279-84. doi: 10.1159/000113039. Epub 2008 Jan 11.

PMID:
18187949
[PubMed - indexed for MEDLINE]
16.

Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.

Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR.

J Clin Oncol. 2002 Mar 1;20(5):1182-91.

PMID:
11870159
[PubMed - indexed for MEDLINE]
17.

Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.

Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S.

J Clin Gastroenterol. 2010 Apr;44(4):286-8. doi: 10.1097/MCG.0b013e3181cda097.

PMID:
20216081
[PubMed - indexed for MEDLINE]
18.

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.

Georgoulias V, Kouroussis C, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E, Polyzos A, Syrigos K, Veslemes M, Toubis M, Ardavanis A, Tselepatiotis E, Vlachonikolis I; Lung Cancer Committee of the Hellenic Oncology Research Group.

Br J Cancer. 2004 Aug 2;91(3):482-8.

PMID:
15238986
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.

Rachamalla R, Malamud S, Grossbard ML, Mathew S, Dietrich M, Kozuch P.

Anticancer Drugs. 2004 Mar;15(3):211-7.

PMID:
15014353
[PubMed - indexed for MEDLINE]
20.

Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.

Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR, Magrinat GC, Bearden JD, Minotto DC, Howerton R, Levine E, Blackstock AW.

Am J Clin Oncol. 2005 Aug;28(4):345-50.

PMID:
16062075
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk